webinar register page

Webinar banner
This webinar is for users with a Zoom account. New to Zoom? Sign up free.
Speech biomarkers in mental health and psychiatry research
Over the past several years, interest in digital health tools and their applications in mental health has increased significantly. Digital technologies enable the collection of high quality phenotypic and behavioural data which has the potential to change the way we diagnose, monitor and develop therapies for psychiatric disease. Among these tools, speech-based biomarkers, including those being developed at Winterlight Labs, show strong potential for remote monitoring, characterizing mental states and objectively tracking changes over time. In this Webinar we will discuss:

- How speech biomarkers can be used in clinical research and drug development?
- How does speech change in different psychiatric conditions?
- The potential prognostic value of measuring speech to track remission and relapse?
- How high frequency monitoring of speech can provide sensitive symptom monitoring?

May 26, 2022 12:00 PM in Eastern Time (US and Canada)

* Required information


Bill Simpson, PhD.
Head of Partnerships @Winterlight Labs
Dr. Bill Simpson has spent the last 15 years working in digital health as a research associate, data analyst, clinical scientist and operations lead. He obtained his PhD in Neuroscience from McMaster University where he studied blood and behaviour based biomarkers for psychiatric disease. Bill is currently the Head of Partnerships at Winterlight Labs and an Adjunct Lecturer in the Department of Psychiatry and Behavioural Neuroscience at McMaster University.
Jessica Robin, PhD.
Director of Clinical Research @Winterlight Labs
Dr. Jessica Robin leads Winterlight Labs' clinical research program, and her research focuses on speech patterns in neurodegenerative disease. Dr. Robin completed her PhD in cognitive neuroscience at the University of Toronto and her postdoc at the Rotman Research Institute, funded by the Alzheimer's Society of Canada.
Sunny Tang, MD.
Assistant Professor, Department of Psychiatry @Feinstein Institutes for Medical Research
Dr. Sunny Tang is an Assistant Professor of psychiatry at the Feinstein Institutes for Medical Research. Her area of expertise is in technology and psychosis, particularly using computational linguistic methods to generate biomarkers for psychosis and related disorders. She has been recognized for her achievements as an early career investigator by the Society of Biological Psychiatry, the Schizophrenia International Research Society, National Institutes of Mental Health, the American Society of Clinical Psychopharmacology, and the Brain and Behavior Research Foundation. Dr. Tang is also co-founder and Chief Science Office of North Shore Therapeutics, which uses immersive technology to deliver solutions for serious mental illness.